In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Hold rating on 4D Molecular Therapeutics (FDMT – Research Report), with a price target of $15.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Kostas Biliouris’s rating is based on a combination of factors concerning 4D Molecular Therapeutics’ development of 4D-150 for wAMD treatment. While the rescue-free rate in the newly-diagnosed cohort is competitive, the extension cohort’s results are less so, which is significant given the crowded market landscape. The safety profile of 4D-150 remains a positive factor, yet the overall commercial potential is tempered by the existing competition and investor concerns about market opportunities.
Biliouris notes that while a potential partnership could boost FDMT’s stock by over 20%, investor skepticism and the current biotech market conditions might limit this upside. Additionally, although upcoming Phase III studies could enhance the drug’s prospects, the timing of competitor data releases poses challenges. These elements contribute to a Hold rating, reflecting a cautious stance amidst both opportunities and uncertainties.
Biliouris covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Legend Biotech, and BridgeBio Pharma. According to TipRanks, Biliouris has an average return of -8.9% and a 33.67% success rate on recommended stocks.